Pluripotency, virtually unlimited self-renewal and amenability to genetic modification make embryonic stem (ES) cells an attractive donor source for cell-mediated gene therapy. In this proof of concept study, we explore whether glial precursors derived from murine ES cells (ESGPs) and engineered to overexpress human arylsulfatase A (hASA) can cross-correct the metabolic defect in an animal model of metachromatic leukodystrophy (MLD). Transfected ES cells showed an up to 30-fold increase in ASA activity. Following in vitro differentiation, high expression of ASA was found in all stages of neural and glial differentiation. hASA-overexpressing ESGPs maintained their ability to differentiate into astrocytes and oligodendrocytes in vitro and in vivo. After transplantation into the brain of neonatal ASA-deficient mice, hASA-overexpressing ESGPs were found to incorporate into a variety of host brain regions. Four weeks after engraftment, immunofluorescence analyses with an antibody to sulfatide revealed a 46.774.0% reduction of immunoreactive sulfatide deposits in the vicinity of the hASA-positive engrafted cells, thereby significantly extending the rate of sulfatide reduction achieved by the endogenous ASA activity of non-hASA-transfected control cells (21.175.8%). These findings provide first in vivo evidence that ES cells may serve as a potential donor source for cell-mediated enzyme delivery in storage disorders such as MLD.
Introduction
Metachromatic leukodystrophy (MLD) is a lysosomal lipid storage disorder caused by the deficiency of arylsulfatase A (ASA; EC 3.1.6.8). This enzyme catalyzes the first step in the degradation pathway of 3-Osulfogalactosylceramide (sulfatide), that is, the desulfation of the galactose moiety. Inability to perform this step results in storage of sulfatide. This membrane lipid is found in various cell types, including gall bladder epithelia, renal tubular cells, certain types of neurons and, in particularly high concentrations, in myelin. For this reason, sulfatide storage in MLD mainly affects oligodendrocytes and Schwann cells, causing a slowly progressive demyelination which results in various neurologic symptoms such as ataxia, spastic tetraparesis, optic atrophy, seizures and dementia. Storage in neurons is likely to contribute to the clinical symptoms, but the degree of contribution is unclear. After years of progression, patients finally die in a decerebrated state. In the typical late infantile form of disease, children develop normally until the age of about 18-24 months. Then, they start to lose previously acquired capabilities and rapidly develop neurological symptoms (for review see von Figura et al.
).
As the disease has only been described in humans and no naturally occurring animal model exists, an ASAknockout mouse was generated some time ago. 2 With increasing age, these mice show progressive sulfatide accumulation, and the tissue distribution of the stored sulfatide closely resembles that of patients. The phenotype of the mice, however, is moderate, because they do not develop demyelination. Aged animals develop merely mild neurological symptoms, which do not limit their lifespan. The cause of these symptoms in the absence of demyelination is unclear, but may result from progressive neuronal storage.
So far, therapy of MLD is limited to symptomatic treatment such as medication for seizure control. In addition, bone marrow transplantation performed in late-onset presymptomatic patients seems to stop progression of the disease. 3 Causative treatment, however, is not available. ASA-deficient mice have been used as a model system for various experimental therapies. Bone marrow stem cell-based gene therapy approaches have yielded ambiguous results. The results of one study suggest a beneficial effect on peripheral nervous system pathology with only marginal effects on the central nervous system (CNS). 4 Biffi et al. 5 have described a complete reversion of peripheral and CNS demyelination, which is rather surprising as these animals are reported to lack a demyelinating phenotype. 2, 6 The same group found that injection of ASA-expressing lentiviral vectors results in an improvement of CNS neuronal pathology in this mouse model. 7 A more conventional strategy to treat storage disorders is direct enzyme replacement -an approach already in clinical use in other lysosomal storage diseases. 8, 9 A recent study demonstrated unexpected reduction of sulfatide storage in peripheral organs as well as the CNS after intravenous application of recombinant human ASA (hASA). 10 An alternative approach is the direct implantation of cells into the nervous system of affected recipients. As ASA secreted by one cell can be endocytosed by neighboring cells and correct their metabolic defect, it is reasonable to modify the implanted cells genetically such that they overexpress ASA. These cells serve as a delivery vehicle to provide enzyme for resident ASAdeficient cells. An attractive donor source for such an approach are embryonic stem cells (ES cells). ES cells can be readily expanded and genetically modified in vitro. As they can be efficiently differentiated into oligodendrocytes, [11] [12] [13] [14] they may not only function as a vehicle for enzyme delivery, but also substitute endogenous oligodendrocytes lost during the disease, as shown recently in an animal model of acute inflammatory demyelination. 15 
Results
Generation of ES cell-derived glial precursors overexpressing hASA ES cells were electroporated with the plasmid pCAGGShASA, which contains the hASA cDNA under transcriptional control of a chicken b-actin promoter with the cytomegalovirus (CMV) early immediate enhancer. This vector is known to yield high transgene expression levels in ES cells, embryos and adult mice. 16 To enable selection and convenient identification of the transfected cells, the ES cells were co-transfected with a plasmid encoding the neo r and lacZ genes. Among 40 selected clones, clone #25 (CJ7-bAc-hASA#25) was chosen based on its high b-galactosidase and hASA expression. Expression levels of the enzyme were determined by Western blot analysis (Figure 1a ) using the anti-hASA antibody 17 and by ASA activity measurements using the artificial substrate paranitrochatechol sulfate (Table 1 ). The ASA activity of the selected clone was 30 times higher than the levels observed in control cells transfected with the neo r /lacZ plasmid only (CJ7-CMV-Neo/lacZ; Table 1 ).
The ES cells were then subjected to an established in vitro differentiation protocol that permits the generation of pan-neural precursors proliferating in the presence of basic fibroblast growth factor (FGF2). 18 By subsequent proliferation in FGF2/EGF (epidermal growth factor) and FGF2/PDGF (platelet-derived growth factor) the cells are gradually shifted into a predominantly glial precursor fate.
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Differentiation of the precursors can be induced by withdrawal of the growth factors at the individual stages. Western blot analyses and the enzyme assay revealed that expression and activity of ASA were maintained throughout this in vitro differentiation process. Moreover, the expression of ASA was increased upon precursor differentiation ; Figure 1a , lanes 3 and 5; Table 1 ). In contrast, CJ7-CMV-Neo/lacZ control cells showed only low levels of endogenous ASA activity throughout the ES cell differentiation paradigm (Table 1) , and no signal could be detected with the anti-hASA antibody in these cells (Figure 1a , lanes 6 and 7). Immunofluorescence analysis of the glial precursors with antibodies to hASA and the lysosomal marker protein LAMP-2 revealed a colocalization of both signals, indicating that the hASA is predominantly localized in the lysosomal compartment (Figure 1b) . Upon a 4-day growth factor withdrawal, hASA-expressing ESGP FGF+EGF DIFF cultures contained both astrocytes expressing the intermediate filament glial fibrillary acidic protein (GFAP) and O4-immunoreactive oligodendrocytes ( Figure 1c ). Quantitative analysis revealed that at this time point, 51.275.1% of the cells expressed GFAP and exhibited a flat morphology typical of cultured astrocytes, and 8.970.9% of this cell population were immunoreactive to O4, an antibody recognizing oligodendrocyte-specific glycolipids.
Transplantation of hASA-overexpressing ES cell-derived glial precursors into the brain of ASA-deficient mice
To facilitate the identification of engrafted donor cells, precursors were transduced with a retroviral vector pREV-PLAP carrying the heat-stable placental alkaline phosphatase before transplantation. The retroviral infection resulted in no alterations in hASA expression levels of the ESGPs (data not shown). In initial experiments, we transplanted mice at 5 weeks of age. The distribution and survival rate of cells derived from these transplants, however, was too limited (data not shown) for a proof of concept study. For this reason, we chose newborn animals. One month after transplantation, the animals were killed, and the paraformaldehyde-fixed brains were processed for histopathological analysis. Up to that time point, all recipient animals survived and displayed no signs of neurological impairment. Serial coronal sections were prepared, histologically examined and processed for alkaline phosphatase histochemistry (Figure 2 ). Small clusters of donor cells were seen at the implant sites, but engrafted cells were also detected several millimeters remote from the sites of injection, indicating active migration through the neuropil. The distribution of the donor cells across the horizontal plane is summarized schematically in Figure 2a . Engrafted donor cells were found in a variety of brain regions including the hippocampal fimbria (Figure 2b ), corpus callosum 
Engrafted hASA-expressing cells reduce sulfatide storage
To study whether engrafted hASA-expressing cells can reduce sulfatide storage, sections adjacent to those containing PLAP-positive cells were double stained with antibodies to sulfatide (SulphI) and hASA. For quantification, a grid of 50 Â 50 mm squares was placed above single hASA-positive cells. According to their distance from the engrafted donor cell, individual squares were grouped into three areas as indicated in Figure 3a . The number of SulphI-immunoreactive deposits was quantified in a z-stack of ten 1 mm optical sections as described in Materials and methods. These measurements revealed that the hASA-expressing cells lead to a clear reduction in sulfatide storage. In the center square containing the engrafted cell (area 1), we observed a 46.774% (mean7s.e.m.; Po0.001) reduction in the number of immunoreactive storage granules as compared to the surrounding control tissue outside the grid. In area 2 (B25-100 mm from the donor cell) and area 3 (B75-175 mm from the donor cell), the reduction of sulfatide deposits still amounted to 27.072.9% (Po0.001) and 20.472.7% (Po0.001), respectively ( Figure 3 ). ECFPtransduced control cells, which do not overexpress hASA, too, elicited a significant reduction in sulfatide storage in area 1, albeit at a lower level (21.175.8%; P ¼ 0.001). In all areas analyzed, hASA-overexpressing cells resulted in significantly higher reduction of sulfa- Abbreviations: ASA, arylsulfatase A; DIFF, differentiation; EGF, epidermal growth factor; ES, embryonic stem cell; ESGP, ES cell-derived glial precursor; FGF, fibroblast growth factor; PDGF, platelet-derived growth factor. ASA activity was determined using the artificial ASA substrate p-nitrochatechol sulfate. Enzymatic activity is expressed as mU/mg protein in cell lysates. Compared to control cells transfected with a plasmid encoding neo r and lacZ, hASA-transfected cells show high ASA activity, which further increases upon differentiation of the ES cell-derived neural precursors. Results are based on three independent experiments and are expressed as mean7s.d.
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tide deposits than the ECFP-transduced control cells ( Figure 3b ). Whereas the recipients of hASA-expressing cells showed a significant increase in sulfatide reduction across all three areas, no significant differences were observed between areas 2 and 3 of the control grafts ( Figure 3b ). These findings indicate that endogenous ASA of control cells affects sulfatide storage in the immediate vicinity of the engrafted cells, but overexpression of hASA permits a more efficient reduction of sulfatide across a larger perimeter.
Discussion
An important feature of many lysosomal enzymes is the fact that once secreted they can be efficiently taken up by neighbor cells where receptor-mediated endocytosis sorts them correctly to the lysosomal compartment. This is not the case for, for example, mitochondrial enzymes, making cross-correction for mitochondrial diseases technically more challenging at this time. , corpus callosum (c-e), the dentate gyrus (f) and cortex (g). In white matter tracts, cells frequently displayed an oligodendrogial morphology with multiple delicate cell processes oriented in parallel along the axon (c and d; arrows). In the hippocampus, engrafted cells were found mainly inside the dentate gyrus (f, dashed lines delineate the granule cell layer). (h and i) Double immunofluorescence with antibodies to hASA (h 1 , i 1 ; green) and the cell type-specific markers GFAP (h 2 ; red) and CNP (i 2 ; red) showed that the hASA-expressing cells maintained the ability to generate astrocytes (h 3 ) and oligodendrocytes (i 3 ). Scale bars: h and i, 10 mm.
ES cell-based sulfatide reduction in an MLD model D Klein et al transcellular enzyme replacement. The feasibility of this approach for MLD treatment was investigated in various studies. Bone marrow stem cell-based gene therapy in ASA-deficient mice can decrease sulfatide storage, but this approach requires very high ASA expression levels, and the therapeutic effect on neurological symptoms prevailing in MLD is disappointing. 4, 19 Intravenous injection of enzymes provides another option, which is already applied clinically in some lysosomal disorders. 8, 9 In the case of ASA, injection of recombinant enzyme leads to sulfatide reduction in peripheral organs and surprisingly -although to a limited extent -also in the brain. 10 Transplantation of ASA-secreting cells into the brain tissue represents an alternative therapeutic strategy that could bypass the limitations imposed by the bloodbrain barrier. A recent study has provided evidence that grafted primary oligodendrocyte progenitors can reduce sulfatide storage in the brain of MLD mutant mice. 20 However, when extrapolated to clinical applications, the application of primary cells is limited by the shortage of donor tissue, batch-to-batch variations typically encountered in primary cell preparations and restricted expandability.
The advent of ES cell technology has provided novel prospects to combine efficient genetic engineering with tissue-specific cell transplantation. Owing to their extensive capacity for self-renewal, their pluripotency and their amenability to genetic modification, ES cells can be used to generate very large numbers of immature and migratory precursors entirely in vitro. A recent in vitro study has shown that ES cells may be used to express biologically active levels of recombinant human a-mannosidase, an enzyme deficient in a-mannosidosis. 21 Here, we explored the feasibility of using ESGPs for the treatment of MLD. We have generated stably transfected ES cells, which produce up to 30 times more ASA than cells transfected with a control vector. We show that hASA expression is maintained and even increased during neural differentiation and does not interfere with the ability of the cells to generate astrocytes and oligodendrocytes.
In the brain of ASA-deficient mice, sulfatide concentration increases continuously, whereas sulfatide levels in the brain of normal mice plateau at 2 months of age. 6 The amount of sulfatide is already twofold increased in newborn ASA-deficient mice, and increase of sulfatide concentration is most prominent in the first 5 months of age. To explore their therapeutic efficacy, we first transplanted hASA-overexpressing ESGPs into the brain of 2-and 4-month-old ASA-deficient mice. However, these experiments resulted in no significant spread of the grafted cells beyond the site of injection (data not shown). We then transplanted hASA-overexpressing cells into the brain of neonatal ASA-deficient mice, a paradigm known to allow widespread delivery of transplanted cells. 22, 23 Four weeks after transplantation, the donor cells were found to be widely distributed in the host brain. A key finding of our study is that the cell transplants result in a significant reduction of sulfatide storage deposits. In young ASA-deficient mice, sulfatide storage is not yet detectable by thin-layer chromatography but only by histochemical staining with alcian blue or immunohistochemistry with a sulfatide antibody. We chose the latter to quantify sulfatide storage granules in the vicinity of transplant-derived cells. The SulphI antibody used in these experiments reacts with sulfatide, seminolipid and lactosylceramide sulfatide. 24 Seminolipid is present only in small amounts in mouse and rat brain. 25 Lactosylceramide sulfate has not been reported to occur in the brain. 6 Thus, in brain sections, the immunoreactivity of the SulphI antibody selectively indicates the presence of sulfatide. Based on this read-out system, we observed a 46.774.0% reduction of sulfatide storage granules around individual hASA-positive cells (area 1). A smaller reduction of sulfatide was also observed after transplantation of cells transfected with a control plasmid -an effect most likely due to the endogenous ASA activity in these cells. In general, the extent of sulfatide reduction strongly correlated with the distance from the incorporated cells. The direct comparison of unmodified and hASA-overexpressing cells in our study shows that the amount of ASA is an important factor influencing the size of the delivery volume of the enzyme. However, in spite of the increased ASA levels, one has to realize that in absolute terms the delivery radius in vivo remains small. Our findings suggest that within a 4-week time period, a single ASA-overexpressing cell may only be able to elicit an B50% reduction of sulfatide deposits in a volume of 2.5 Â 10 4 mm
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. This result predicts that large numbers of cells and multiple injections would be required to enable a global delivery of the enzyme to the host brain -a problem particularly relevant to the translation of such an approach to brains of larger mammals and humans. Extrapolating the size of a mouse brain to a human brain, the current approach would, theoretically, require dozens of injections or even more to ensure widespread distribution of the donor cells. This problem is of course not unique to MLD but applies to all diseases affecting the nervous system globally. Clinical strategies for stem cell-based enzyme delivery may thus have to include techniques that enhance the migration potential of the transplanted cells. In addition, it would be desirable that proliferation of grafted cells can be temporally enhanced and controlled.
As sulfatide is found in particularly high concentrations in myelin, oligodendrocytes and Schwann cells are prime therapeutic targets of MLD. Transplantation of ASA-overexpressing cells into the brain aims to correct the metabolic defect in oligodendrocytes only. Most likely this approach will have no effect on the peripheral nervous system. It has been shown recently that the peripheral nervous system can be positively affected by enzyme-replacement therapies. 10 Thus, in the future, a combination of transplantation of cells into the CNS combined with enzyme-replacement therapy may provide a feasible therapeutic option.
In addition to oligodendrocytes and Schwann cells, ASA-deficient mice have been shown to accumulate sulfatide in some astrocytes 6 and in a considerable number of neurons. 26, 27 ESGPs have been shown to efficiently give rise to oligodendrocytes and astrocytes and to repair myelin in models of hereditary and inflammatory demyelination. 11, 13, 15, 28 Similarly, the hASA-transfected ES cells used in this study were found to generate both glial cell types in vitro and in vivo. Thus, ES cell-based therapies for MLD may eventually not only be used for enzyme delivery but also to replace oligodendrocytes and repair myelin destroyed during the disease process. Our current transplant data indicate that the majority of the engrafted cells differentiate into astrocytes. This could be owing to the lack of demyelination in the brain of the ASA-deficient mice as myelin or oligodendrocyte deficiency might be required to promote oligodendroglial differentiation. On the other hand, ASA-deficient mice were reported to exhibit a significant degree of reactive astrogliosis. 2, 6 Thus, the ASA mutant employed in this study might not be appropriate to assess the remyelination potential of the grafted precursors.
Importantly, no teratoma formation was detected in any of the transplant recipients. In a previous study, Erdo et al. 29 have reported that ES cell-derived neural precursors exhibit pronounced tumorigenicity in homologous mouse-to-mouse but not in xenogeneic mouse-torat transplants. Our findings, along with those of others, 30 indicate that the risk of teratoma formation in homologous transplants can be reduced by stringent protocols for neural differentiation. Thus, tumorigenicity seems to be related primarily to the purity of the ES cellderived precursors rather than the species of the transplant recipient. However, it must be emphasized that our studies are short-term experiments and that longer postoperative follow-up periods are required to comprehensively assess the safety of this approach.
Different lysosomal storage diseases may exhibit different amenability to cell therapy
A variety of cell types have been used for enzyme delivery in mouse models of lysosomal storage disease. A comparative discussion of these studies is certainly difficult, as the degree of storage of different compounds and activities of different enzymes cannot be directly related. In spite of these obstacles, it becomes obvious that various factors influence the therapeutic efficacy of an enzyme secreted by a transplanted cell. Niemann Pick Type A mice lack sphingomyelinase and store sphingomyelin. Neural progenitor cells isolated from an adult mouse were modified to overexpress sphingomyelinase about sevenfold and transplanted into the brain of the respective mouse model. 31 Histochemical analysis of storage revealed a reduction of sphingomyelin in the vicinity of the graft, extending B2-4.6 mm into the adjacent host tissue. In our study the distance of clearance around single hASA-overexpressing cells in one dimension is only in the range of 100-200 mm. Considering this difference, one would expect that wildtype cells already suffice to yield a potent effect in Niemann Pick mice. Yet, in contrast to the sulfatide reduction obtained with ECFP-transduced control cells in our model, no reduction of sphingomyelin was observed upon transplantation of wild-type cells in the Niemann Pick model. This may be explained by the extremely low secretion rate of endogenous sphingomyelinase in non-overexpressing cells. Thus, in contrast to ASA, overexpression is a prerequisite for secretion of sphingomyelinase. However, once the sphingomyelinase is secreted, it seems to be able to clear a much larger volume of sphingomyelin than ASA is able to clear from sulfatide. This phenomenon may also be owing to different doses of enzyme required to reduce accumulation of a certain compound. It is generally assumed that already low amounts of enzyme are sufficient to reduce lipid storage considerably. This is demonstrated, for example, by the low doses of glucocerebrosidase required for enzyme replacement and glucosylceramide reduction in Gaucher patients. 32 In contrast, bone marrow stem cell-based gene therapy trials in ASAdeficient mice suggested that unexpectedly high levels of ASA are necessary to reduce sulfatide storage. Thus, ES cell-based sulfatide reduction in an MLD model D Klein et al water-soluble glycosaminoglycans may need lower amounts of enzyme for degradation than water-insoluble lipid aggregates. In fact, transplantation of b-glucuronidase-expressing neural progenitor cells into the brain of mucopolysaccharidosis mice led to a reduction and in the case of transplantation of b-glucuronidase overexpressing bone marrow stromal cells to an almost complete normalization of glycosaminoglycan storage in the treated animals. 22, 33 These diverse results indicate that the therapeutic efficacy of cell-based enzyme delivery cannot be generalized for all lysosomal storage disorders but depends critically on disease-specific parameters such as secretion rates, diffusion distance and interaction with the storage compound.
In summary, the results of our study demonstrate that ES cells engineered to express hASA can be efficiently differentiated into neural precursors and neuroglia exhibiting strongly increased ASA activity. Transplantation experiments in neonatal ASA-deficient mice indicate that these cells can significantly reduce sulfatide storage within an observation period of at least 4 weeks. These findings lend further support to the notion that donor cell-based 'cross-correction' provides a valid principle for the treatment of lysosomal storage disorders.
Materials and methods

Materials
Unless otherwise stated, chemicals were obtained from Sigma (Steinheim, Germany), Merck (Darmstadt, Germany) or Calbiochem-Novabiochem (Schwalbach, Germany). The plasmid pCAGGS was a kind gift from M Okabe (Osaka University, Osaka, Japan). The pcDNA3-b-Gal plasmid was from Invitrogen (Karlsruhe, Germany).
Construction of the plasmid pCAGGS-hASA
The pCAGGS-hASA (6.3 kb) plasmid was constructed by inserting a XhoI-XhoI fragment containing the hASA cDNA (1521 bp) into the XhoI site of the pCAGGS plasmid (4.8 kb; M Okabe, Osaka, Japan). The resulting pCAGGS-hASA plasmid contained the cDNA of the hASA under transcriptional control of the chicken b-actin promoter with the CMV early immediate enhancer (CMV-IE enhancer). 16 The entire coding region of the hASA cDNA was obtained by digestion of the plasmid MFCV-hASA with EcoRI. 34, 35 PCR primers for generating a XhoI-XhoI fragment containing the hASA cDNA were as follows: XhoI-hASA-353 forward primer, 5 0 -AAA CTC GAG ATG TCC ATG GGG GCA CCG CGG TCC-3 0 ; hASA-1882-XhoI backward primer, 3 0 -AAA CTC GAG TCA GGC ATG GGG ATC TGG GCA ATG G-5 0 .
Transfection and ES cell culture
Mouse ES cells (8 Â 10 6 ) from line CJ7 36 were coelectroporated with the pCAGGS-hASA plasmid (100 mg) and the pcDNA3-b-Gal plasmid (20 mg) using a BioRad gene pulser (230 V, 500 mF). A control population was generated by transfection with the pcDNA3-b-Gal plasmid (40 mg) only. The pcDNA3-b-Gal plasmid contains a G418 resistance gene as well as a lacZ gene under the control of a CMV promoter and allowed the selection of G418-resistant ES cell clones with 400 mg/ml G418 on g-irradiated multiple-drug-resistant murine embryonic fibroblasts (gmdrMEFs). 37 ES cell clones were expanded on gmdrMEFs in the presence of G418 and 1000 U/ml leukemia inhibitory factor (Chemicon, Hofheim, Germany) and screened for ASA expression with the ASA activity assay. Differentiation of ES cells to glial precursor cells (ESGPs) was performed according to Brü stle et al.
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For a detailed protocol, see Schmandt et al. 38 ESGPs were propagated in FGF2 (10 ng/ml) and EGF (20 ng/ml; ESGP
FGF+EGF
). An additional culture step in the presence of FGF2 and PDGF-AA (both 10 ng/ml) was used to obtain oligoastrocytic precursors (ESGP FGF+PDGF ). In vitro differentiation into astrocytes and oligodendrocytes was induced by growth factor withdrawal (ESGP FGF+EGF DIFF and ESGP FGF+PDGF DIFF ). All growth factors were obtained from R&D Systems (Wiesbaden, Germany).
ASA activity assay
Cells were grown to confluency in six-well tissue culture plates. Cell extracts were obtained by cell lysis in ice-cold Tris-buffered saline (TBS)/0.5% Triton X-100 supplemented with protease inhibitors (1 mM iodoacetamide, 1 mM phenylmethanesulfonyl fluoride and 5 mM ethylenediaminetetraacetic acid (EDTA)), followed by a 5 min centrifugation at 11 000 g. ASA activity in cell lysates was determined with the artificial substrate p-nitrochatechol sulfate. 39 Fifty microliters of each sample was incubated for 30 min at 371C with p-nitrochatechol sulfate in 0.5 M sodium citrate-phosphate buffer (pH 5) containing 10% NaCl (w/v) and 0.2% bovine serum albumin (BSA) (w/ v). The reaction was stopped by addition of 500-750 ml 1 M NaOH and absorbance was measured at 515 nm on a Beckman DU640 spectrophotometer (Beckman-Coulter, Krefeld, Germany). ASA activity of supernatants and total cell extracts was related to protein content determined by the DC protein assay (BioRad, Mü nchen, Germany).
Western blot analysis
Protein samples (50-100 mg of protein) were separated on 10% polyacrylamide gels and transferred to nitrocellulose membranes (BioRad), for 1.5 h at 0.8 mA/cm 2 in a semi-dry electrophoretic transfer cell as recommended by the manufacturer (BioRad). The membranes were rinsed and nonspecific protein binding sites were blocked by a 2-h incubation with 5% skim milk/PBS (phosphate-buffered saline). Membranes were incubated with primary antibody rabbit anti-hASA BE#3 (1/1000) overnight at 41C in blocking solution diluted 1/3 in PBS. 17 After incubation with a secondary peroxidaseconjugated goat anti-rabbit antibody (1/10 000; Jackson IR Laboratories, West Grove, PA, USA), signals were detected with the enhanced chemiluminescence system from Amersham. 
Retroviral infection of ES cell-derived glial precursors
Retroviruses expressing PLAP(pREV-PLAP) and neomycin phosphotransferase (neo r ) or ECFP (pREV-ECFP) and neo r were produced from stably transfected GP+E-86 helper cells 40, 41 and used to transduce hASA-overexpressing and wild-type ESGP FGF+EGF for reliable identification of transplanted cells. Two days before transduction, helper cells were plated at a density of 3 Â 10 6 cells per 10 cm dish. After 24 h, the medium was switched to serum-free Dulbecco's modified Eagle's medium/F12. Twenty-four hours later, the medium was harvested, filtered through 0.45 mm pore filters and immediately used for transduction. ESGP FGF+EGF were plated at a density of 3 Â 10 6 cells per 10-cm dish. After 24 h, the cells were incubated for 2 h with polybrene (4 mg/ml) and subsequently exposed to the supernatant of the transfected packaging cell lines. Fresh medium was added after another 3 h. A complete medium change was performed after 20 h. Two days after transduction, cells were selected with G418 (200 mg/ml) for 2-3 passages before they were used for experiments.
Preparation and transplantation of ES cell-derived precursors
ESGP
FGF+EGF cultures were rinsed 3 Â in Hank's buffered saline solution (HBSS, Invitrogen), trypsinized and neutralized with trypsin inhibitor. Cells were centrifuged at 1000 r.p.m. at 41C and the pellet was resuspended in HBSS with 0.1% DNase. Cells were thereafter concentrated to 75 000 cells/ml in HBSS and transplanted immediately. All recipient animals (n ¼ 20) were housed under standard laboratory conditions, and the surgical procedures were performed according to the institutional guidelines on the use of laboratory animals. Two-day-old (P2) ASA-deficient mice were shortly anesthetized by hypothermia on crushed ice. Cells were grafted using a flame-polished glass micropipette of 75 mm internal diameter. A total of two injections per animal (300 000 cells/animal) targeting the frontal part of the right hemisphere were performed (150 000 cells/injection in a volume of 2 ml). Cells were injected through the skin and meninges in less than 1 min to minimize mortality. With this transplantation technique, all animals survived the surgical procedure.
Tissue processing and immunohistochemistry
Fourteen to 28 days after transplantation, mice were killed under deep anesthesia (intraperitoneal injection of tribromethanol; 1 mg/kg body weight), followed by transcardial fixation with 4% paraformaldehyde in 0.1 M PBS. Brains were post-fixed at 41C overnight, cryoprotected in 20% sucrose in 0.1 M PBS for at least 3 days and cut in a freezing microtome in the horizontal plane. Sections (20 mm) were serially collected on SuperFrostplus glass slides (Meinzl Glaeser, Germany) and stored at À801C.
To assay alkaline phosphatase (heat stable) activity in the transplanted brains, serial 20 mm frozen sections were incubated for 30 min in pre-warmed PBS (651C) followed by an incubation at 371C in 100 mM Tris/HCl pH 9.5/ 100 mM NaCl/50 mM MgCl 2 , nitroblue tetrazolium at 0.3 mg/ml and 5-bromo-4-chloro-3-indolyl phosphate at 0.175 mg/ml. After 5-15 min, the staining was stopped by transferring the sections to 10 mM Tris/HCl pH 9/1 mM EDTA.
The method used for sulfatide immunohistochemistry was described by Pernber et al. 42, 43 Briefly, frozen sections of perfusion-fixed brains were first incubated with 0.05% glycine in PBS for 30 min to reduce unreacted aldehydes. Permeabilization with 0.05% Tween 20 and blocking with 1% BSA in PBS was performed in one step overnight at 41C. All antibodies were diluted in 0.01% Tween 20/1% BSA in PBS. Rinsing in PBS (3 Â 10 min) was performed between each incubation step. The sections were incubated with the monoclonal mouse anti-SulphI antibody (20 mg/ml; kindly provided by P Fredman, Sahlgrenska University Hospital, Mö lndal, Sweden) overnight at 41C. For indirect double immunolabeling of hASA-overexpressing cells, the polyclonal rabbit antihASA antibody BE#3 (1/500) was added in addition. In the case of ECFP-expressing ESGPs, double immunofluorescence analysis was performed with the polyclonal rabbit anti-GFP antibody (1/4000; Abcam, Cambridge, UK) to enhance the ECFP signal. Thereafter, tissue sections were incubated with blocking solution for 30 min at rt to block unspecific binding of the secondary antibodies. Incubation with Cy3-conjugated goat antimouse and Cy2-conjugated goat anti-rabbit secondary antibodies (diluted 1/500 in blocking solution, Jackson IR Laboratories) for 3-4 h was carried out at rt. To analyze the differentiation potential of transplanted hASA-overexpressing cells, the tissue was incubated with anti-hASA antibody BE#3 (1/250) or anti-GFP antibody and either an antibody to GFAP (1/500; MP Biomedicals Inc., Aurora, OH, USA), CNP (1/1000; Abcam) or RIP (monoclonal mouse, 1/100; developed by S Hockfield, obtained from the Developmental Studies Hybridoma Bank). Specimens were blocked for 30 min in 10% fetal calf serum (FCS) and 0.1% Triton X-100 in PBS for 30 min. Primary antibodies were ES cell-based sulfatide reduction in an MLD model D Klein et al incubated overnight at rt in 5% FCS and 0.1% Triton X-100 in PBS. Cy3-conjugated goat anti-mouse and Cy2-conjugated goat anti-rabbit secondary antibodies (diluted 1/500 in 5% FCS and 0.1% Triton X-100 in PBS) were incubated at rt for 2 h. Nuclei were counterstained with DAPI in PBS for 8 min. Specimens were mounted and examined on Zeiss Axioplan, Axiovert and Laser Scan microscopes.
Quantification of sulfatide storage
For quantification of sulfatide storage, photographs were recorded under standardized conditions (z-stack of 10 adjacent 1 mm optical sections) with a Laser Scanning Microscope (LSM510, Zeiss). Only micrographs containing a single hASA-immunoreactive cell were used for quantification. Following compression of the optical stacks into a single plane, a 50 Â 50 mm square grid was placed above each hASA-expressing cell as outlined in Figure 3a . Structures immunoreactive for the SulphI antibody were counted in each square. The center square containing the hASA-overexpressing donor cell was defined as area 1. The eight adjacent squares were referred to as area 2. The 16 outermost squares were defined as area 3. The number of sulfatide-positive deposits was averaged for each area and related to values obtained from fifteen 50 Â 50 mm control squares within the same anatomical compartment but outside areas 1-3. Sulfatide reduction within areas 1-3 was expressed as percentage of these control values. Serial brain sections of transplants harboring ECFP-transduced ESGP FGF+EGF were used as control. These sections were immunostained with antibodies to GFP and sulfatide and analyzed in the same manner as described for the hASA-overexpressing cells. Overall quantitation is based on a total of 61 hASA-positive and 30 ECFP-expressing donor cells recruited from six transplant recipients.
Statistical analysis
Quantification of immunolabeled monolayer cultures was based on 20 high-power fields per experiment and a minimum of three independent experiments for each marker. Statistical analysis was performed using the 'Statistical Package for the Social Sciences' (SPSS). For each area, an independent-sample t-test was performed to address the question whether transplantation of ASAoverexpressing ESGPs results in a significantly higher sulfatide granule reduction than ECFP-transduced control cells. For each donor cell type, a paired-sample t-test was performed to identify differences in sulfatide reduction between the different areas. P-values o0.05 were regarded significant.
